Valiant Laboratories Limited (NSE:VALIANTLAB) filed newspaper publication copies of its standalone and consolidated audited financial results for the quarter ended June 30, 2026, with BSE and NSE on August 12, 2026, as required under Regulations 30 and 47 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
Key Highlights
- Standalone total income from operations for Q1 FY27 stood at Rs 7,427.37 lakh, compared with Rs 5,167.85 lakh in Q1 FY26, reflecting strong year-on-year growth.
- Standalone net profit after tax for the quarter was Rs 947.88 lakh, up from Rs 181.56 lakh in the corresponding quarter of the previous year.
- Consolidated net profit after tax for Q1 FY27 was Rs 2,110.30 lakh, against Rs 182.09 lakh in Q1 FY26.
- The board of directors approved the financial results at their meeting held on August 10, 2026, following review by the Audit Committee.
About the Company
Valiant Laboratories Limited (NSE:VALIANTLAB, BSE:543998) is a Mumbai-headquartered pharmaceutical company incorporated in 2021 under CIN L24299MH2021PLC365904. The company operates in the pharma and healthcare sector, with its registered office located at Mulund (West), Mumbai, Maharashtra. It prepares its financial statements in accordance with Indian Accounting Standards (IndAS) as prescribed under Section 133 of the Companies Act, 2013.
Announcement in Detail
The company submitted copies of newspaper publications of its standalone and consolidated audited financial results for the quarter ended June 30, 2026. The results were published in the Financial Express (English) and Mumbai Lakshadeep (Marathi) on August 12, 2026. The filing was made in compliance with Regulations 30 and 47 of the SEBI LODR Regulations, 2015, and the results were also uploaded to the company's official website.
On a standalone basis, total income from operations reached Rs 7,427.37 lakh in Q1 FY27, while net profit before tax was Rs 1,272.80 lakh and net profit after tax was Rs 947.88 lakh. Basic and diluted earnings per share stood at Rs 1.75 for the quarter. Paid-up equity share capital remained at Rs 5,431.25 lakh. The full financial results were previously filed under Regulation 33 and are available on the BSE and NSE portals.
Impact on Investors
Investors will note that the standalone net profit after tax of Rs 947.88 lakh in Q1 FY27 compares with Rs 181.56 lakh in Q1 FY26, representing a substantial year-on-year improvement. The consolidated net profit after tax similarly improved to Rs 2,110.30 lakh from Rs 182.09 lakh in the year-ago quarter. The filing shows basic earnings per share on a standalone basis rose to Rs 1.75 from Rs 0.42 in Q1 FY26.
Shareholders will observe that the consolidated figures for the full year ended March 31, 2026, showed a net profit after tax of Rs 175.87 lakh against a net loss of Rs 326.79 lakh for the year ended March 31, 2025, indicating a return to profitability at the consolidated level. The disclosed terms indicate no exceptional items were reported in Q1 FY27 at either standalone or consolidated level.
Sector / Market Context
India's pharmaceutical sector is among the country's largest export-oriented industries, with the Indian Pharmaceutical Alliance and FICCI citing sustained domestic formulations demand as a key revenue driver for mid-sized manufacturers. Regulatory compliance requirements under SEBI LODR, including mandatory newspaper publication of financial results under Regulation 47, apply to all listed pharmaceutical companies and are a standard periodic disclosure obligation that does not in itself indicate any change in business strategy or outlook.